Adjuvant Atezolizumab: No Survival Benefit in Triple-Negative Breast Cancer

Adding checkpoint inhibition immunotherapy to adjuvant chemotherapy did not improve survival among patients with triple-negative breast cancers.   These findings from a study reported at the 14th European Breast Cancer Conference were presented by Heather McArthur, MD, MPH, Clinical Director of Breast Cancer and Komen Distinguished Chair in Clinical Breast Research at the University of Texas Southwestern Medical Center.   After McArthur’s talk in Italy, she shared the details with Peter Goodwin, OncTimesTalk correspondent.